| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 10/26/2004 | US6809176 Compounds for use in treatment of cancer |
| 10/26/2004 | US6809115 Mixture has a synergistic, weight loss effect |
| 10/26/2004 | US6809111 Antiinflammatory agents; analgesics |
| 10/26/2004 | US6809082 Synthetic transfection vectors |
| 10/26/2004 | US6809077 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration |
| 10/26/2004 | US6809076 Administering anticoagulant agent |
| 10/26/2004 | US6808930 Labelling reagent; can be used in diagnosis and therapy of cancer/tumors; detection of penetration of nucleus susceptible to alpha-lactalbumin (mal) |
| 10/26/2004 | US6808739 Drying method for selectively removing volatile components from wet coatings |
| 10/26/2004 | US6808721 Methods for coating pharmaceutical core tablets |
| 10/26/2004 | US6808719 Interior core in well containing active materials; aperture to exterior |
| 10/26/2004 | US6808712 Imunogenic a beta fragment linked to immunoglobulin carrier to form conjugate; adjuvant comprising antibodies to a beta fragment enhances immune response; alzheimer*s disease treatment |
| 10/26/2004 | US6808706 Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
| 10/26/2004 | US6808705 For suppressing the proliferation of cancer cells |
| 10/26/2004 | US6808522 Microchip devices for delivery of molecules and methods of fabrication thereof |
| 10/26/2004 | CA2395217C Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 10/26/2004 | CA2314151C Polyhydroxyalkanoate compositions having controlled degradation rates |
| 10/26/2004 | CA2295752C Novel process for manufacturing paroxetine solid dispersions |
| 10/26/2004 | CA2294247C Antioxidant enhancement of therapy for hyperproliferative conditions |
| 10/26/2004 | CA2276730C Emulsion vehicle for poorly soluble drugs |
| 10/26/2004 | CA2234140C Stable freeze-dried pharmaceutical formulation |
| 10/26/2004 | CA2161004C Active ingredient patch |
| 10/22/2004 | CA2465017A1 Reagents for detecting efavirenz |
| 10/21/2004 | WO2004089984A1 Antigen recognizing antibody |
| 10/21/2004 | WO2004089869A1 New non-ionic surfactants for solubilizing poorly soluble molecules |
| 10/21/2004 | WO2004089819A1 Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry |
| 10/21/2004 | WO2004089818A1 Functionalized carbon nanotubes, a process for preparing the same and their use in medicinal chemistry |
| 10/21/2004 | WO2004089427A1 Stable carprofen composition |
| 10/21/2004 | WO2004089422A2 Methods of treating and monitoring systemic lupus erythematosus in individuals |
| 10/21/2004 | WO2004089421A2 Methods for rational pegylation of proteins |
| 10/21/2004 | WO2004089420A1 Polyethylene glycol conjugates releasing nitric oxide |
| 10/21/2004 | WO2004089419A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | WO2004089418A1 A fluoroquinolone aqueous formulation of a ph between 4 and 7 comprising i.a. cyclodextrin, hydroxyacid |
| 10/21/2004 | WO2004089417A1 Drug-enclosing multilayer structure particulate and process for producing the same |
| 10/21/2004 | WO2004089406A1 Topical composition in the form of a gel for treating skin burns |
| 10/21/2004 | WO2004089401A1 Remedy for ischemia |
| 10/21/2004 | WO2004089400A1 Remedy for cardiomyopathy |
| 10/21/2004 | WO2004089388A1 The ready-prepared chinese medicine for treatment of hair loss and process of manufacturing thereof |
| 10/21/2004 | WO2004089381A1 Prostaglandin compositions and their use for the treatment of vasospasm |
| 10/21/2004 | WO2004089355A2 Compositions for treating microbial and parasitic infections in cattle and other animals |
| 10/21/2004 | WO2004089345A1 Bone targeting of biodegradable drug-containing nanoparticles |
| 10/21/2004 | WO2004089341A1 Organic compounds |
| 10/21/2004 | WO2004089339A2 Lipid particles having asymmetric lipid coating and method of preparing same |
| 10/21/2004 | WO2004089338A1 A arbidol clathrate and its preparation process and the use thereof |
| 10/21/2004 | WO2004089337A1 Oral administration form for veterinary use |
| 10/21/2004 | WO2004089334A2 Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems |
| 10/21/2004 | WO2004089283A2 Compositions and methods for treating viral infections |
| 10/21/2004 | WO2004080284A3 Antibody-targeted photodynamic therapy |
| 10/21/2004 | WO2004075900A3 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| 10/21/2004 | WO2004075824A3 Pharmaceutical compositions for nasal delivery |
| 10/21/2004 | WO2004075822A3 Pharmaceutical composition for transdermal or transmucosal administration |
| 10/21/2004 | WO2004071402A3 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR |
| 10/21/2004 | WO2004050012A3 Ifosfamide compositions for parenteral administration and a process for their preparation |
| 10/21/2004 | WO2004045542A3 Therapeutic bioconjugates |
| 10/21/2004 | WO2004044222A3 Polymeric prodrugs of vancomycin |
| 10/21/2004 | WO2004010939A3 Methods of using non-human animal apoliprotein a-i protein |
| 10/21/2004 | WO2003100081A3 Biologically active maleamic acid derivatives with labile amide bonds |
| 10/21/2004 | WO2003093793A3 Binary or polynary targeting and uses thereof |
| 10/21/2004 | WO2003043631A3 Method for identification of tumor targeting enzymes |
| 10/21/2004 | WO2003024392A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/21/2004 | US20040210950 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (CALSARCINS) |
| 10/21/2004 | US20040210041 Multimeric proteins for use in the treatment and detection of cell proliferative disorders |
| 10/21/2004 | US20040210040 Monoclonal antibodies for use in the prevention and treatment of cell proliferative and skin disorders; immunotherapy; antitumor agents |
| 10/21/2004 | US20040210039 Keratin-based products and methods for their productions |
| 10/21/2004 | US20040209966 Aqueous air foam |
| 10/21/2004 | US20040209955 preservative-free aqueous solution of sodium gamma-hydroxybutyrate, and a pH adjusting agent; pH of 6-7.5; chemically stable and resistant to microbial growth |
| 10/21/2004 | US20040209919 2-[(2-pyridyl)methylsulfinyl]benzimidazole derivative stabilized with an inorganic salt of magnesium, calcium, potassium, or sodium; gastric acid secretion inhibitors |
| 10/21/2004 | US20040209911 Mixture containing rapamycin; absorption efficiency |
| 10/21/2004 | US20040209909 in a carrier effective to permit sustained release at a therapeutically effective rate over an administration period of at least 8 hours |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209855 use of estradiol metabolites such as 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol; few side effects |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209842 Modification of biopolymers for improved drug delivery |
| 10/21/2004 | US20040209832 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 10/21/2004 | US20040209815 Compositions providing for increased IGF-I solubility |
| 10/21/2004 | US20040209802 Administering erythropoietin or derivative to treat diabetes |
| 10/21/2004 | US20040209797 comprises protein transduction domains; nuclear localization sequences; fusion proteins; for reversible immortalization of cells |
| 10/21/2004 | US20040209366 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 10/21/2004 | US20040208938 for needles comprising time release microparticles containing risperidones, glycolic acid-lactic acid copolymer binders, and high viscosity aqueous fluids (containing sodium carboxymethyl cellulose as modifier) |
| 10/21/2004 | US20040208934 Dispersions or complexes of calcium phosphate in polymers such as polyethylene glycol or dextran sulfate; solid matrix due to hydration; contains active agent; matrix polymer and/or complexing agent slows release of active agent from solid matrix |
| 10/21/2004 | US20040208930 produced by coating core particles with layer containing water-soluble drug and forming film layer containing water-insoluble polymer and plasticizer on particles and forming water-soluble filler layer between water-soluble drug-containing layer and film layer |
| 10/21/2004 | US20040208927 Process for preparing non-hygroscopic sodium valproate composition |
| 10/21/2004 | US20040208926 comprising sertraline and a solubilizing agent which increases the solubility of sertraline in aqueous chloride ion-containing use environments, in particular digestive fluids of the gastrointestinal tract |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208921 Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| 10/21/2004 | US20040208920 injectable liposomal composition for delivery of large amounts of water-soluble substance comprises a plurality of liposomal vesicles having a high weight ratio of lipid to encapsulated water-soluble substance which is distributed over the liposomal vesicles; high efficiency of encapsulation |
| 10/21/2004 | US20040208918 administering constituent which effects a local increase in temperature and/or an increase in blood flow of the skin in addition to the transdermally applied active substance |
| 10/21/2004 | US20040208914 Topical preparation and method for transdermal delivery and localization of therapeutic agents |
| 10/21/2004 | US20040208906 Pharmaceutical composition for topical administration |
| 10/21/2004 | US20040208889 Pharmaceutical use for secreted bacterial effector proteins |
| 10/21/2004 | US20040208884 Administering construct in conjugated or unconjugated form and in combination with immunogenic carrier to induce antibodies; anticarcinogenic agents |
| 10/21/2004 | US20040208875 Method for treating amyloidosis |
| 10/21/2004 | US20040208866 Methods of regulating body weight |
| 10/21/2004 | US20040208860 Use of emu oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations |
| 10/21/2004 | US20040208854 Methods and compositions for controlled release of bioactive compounds |
| 10/21/2004 | US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents |
| 10/21/2004 | US20040208844 Products and drug delivery vehicles |
| 10/21/2004 | US20040208824 Covalent bonded to a chelator 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid, and labeled with a metal ion of a radionuclide; use as drugs and diagnostic purpose; lymphoma, leukemia, myeloma, lupus erythrematosus, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes, asthma |
| 10/21/2004 | US20040206703 Circulating liquid in conduit; injecting ions into fluid flow; controlling concentration profile; salt formation |
| 10/21/2004 | DE10314082A1 Biodegradierbares injizierbares Implantat Biodegradable injectable implant |
| 10/21/2004 | DE10313272A1 Using hexadecylphosphocholine for treatment of actinic keratosis, by topical application as aqueous solution |